NAPSR News: FDA approves Baxter's Hyqvia To Treat Primary Immunodeficiency (PI)

WASHINGTON - Sept. 15, 2014 - PRLog -- Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI). This represents the first subcutaneous immune globulin (IG) treatment with a required dosage of only one infusion up to once per month and one injection site per infusion to administer full therapeutic dose of immune globulin.

"Today's FDA approval of HYQVIA is a significant milestone for Halozyme as it represents the first U.S. approved Biologics License Application which utilizes our rHuPH20 platform," commented Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I would like to thank the talented teams at both Halozyme and Baxter for their dedication to bring a new treatment alternative to PI patients managing a life-long disease."

The launch of HYQVIA is expected to come to fruition in a few weeks. Market analysts expect sales of $800 million per year which will be a substantial revenue boost to Baxter’s spinoff biopharma unit called Baxalta.

With such industry leaders paving the way with new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/